Cargando…

Primary alterations during the development of hidradenitis suppurativa

BACKGROUND: Hidradenitis suppurativa (HS) is a chronic, inflammatory disease of the apocrine gland‐rich (AGR) skin region. The initial steps of disease development are not fully understood, despite intense investigations into immune alterations in lesional HS skin. OBJECTIVES: We aimed to systematic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dajnoki, Z., Somogyi, O., Medgyesi, B., Jenei, A., Szabó, L., Gáspár, K., Hendrik, Z., Gergely, P., Imre, D., Póliska, S., Törőcsik, D., Zouboulis, C.C., Prens, E.P., Kapitány, A., Szegedi, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Acne, Rosacea and Hidradenitis Suppurativa
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298903/ https://www.ncbi.nlm.nih.gov/pubmed/34724272 http://dx.doi.org/10.1111/jdv.17779

Ejemplares similares

A novel nicastrin mutation in a three‐generation Dutch family with hidradenitis suppurativa: a search for functional significance
por: Vossen, A.R.J.V., et al.
Publicado: (2020)

Surgical outcomes and the impact of major surgery on quality of life, activity impairment and sexual health in hidradenitis suppurativa patients: a prospective single centre study
por: Prens, L.M., et al.
Publicado: (2019)

Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials
por: van der Zee, H.H., et al.
Publicado: (2019)

Creation of a severity index for hidradenitis suppurativa that includes a validated quality‐of‐life measure: the HIDRAscore
por: Marzano, A.V., et al.
Publicado: (2020)

Real‐world effectiveness of adalimumab in patients with moderate‐to‐severe hidradenitis suppurativa: the 1‐year SOLACE study
por: Gulliver, W., et al.
Publicado: (2021)

Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real‐world results from the HARMONY Study
por: Hafner, A., et al.
Publicado: (2021)

Baseline patient‐reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice
por: Kimball, A.B., et al.
Publicado: (2020)

Long‐term safety and efficacy of trifarotene 50 μg/g cream, a first‐in‐class RAR‐γ selective topical retinoid, in patients with moderate facial and truncal acne
por: Blume‐Peytavi, U., et al.
Publicado: (2019)

Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers
por: Vossen, A.R.J.V., et al.
Publicado: (2018)

HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa
por: Peris, K., et al.
Publicado: (2019)

The influence of exposome on acne
por: Dréno, B., et al.
Publicado: (2018)

Papulopustular rosacea and rosacea‐like demodicosis: two phenotypes of the same disease?
por: Forton, F.M.N., et al.
Publicado: (2018)

Acne relapses: impact on quality of life and productivity
por: Dreno, B., et al.
Publicado: (2019)

New Data on the Features of Skin Barrier in Hidradenitis Suppurativa
por: Somogyi, Orsolya, et al.
Publicado: (2023)

Consensus on the treatment of hidradenitis suppurativa - Brazilian Society of Dermatology
por: Magalhães, Renata Ferreira, et al.
Publicado: (2019)

New treatments and new assessment instruments for Hidradenitis suppurativa
por: van Straalen, Kelsey R., et al.
Publicado: (2022)

Immunotopographical Differences of Human Skin
por: Béke, Gabriella, et al.
Publicado: (2018)

Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa
por: Gulliver, Wayne, et al.
Publicado: (2016)

Regional Differences in the Permeability Barrier of the Skin—Implications in Acantholytic Skin Diseases
por: Kapitány, Anikó, et al.
Publicado: (2021)

Comparison of Immune and Barrier Characteristics in Scalp and Skin Psoriasis
por: GÁSPÁR, Krisztián, et al.
Publicado: (2020)

High and discordant prevalences of clinical and sonographic enthesitis in patients with hidradenitis suppurativa
por: van Straalen, K.R., et al.
Publicado: (2020)

Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study
por: Prens, L.M., et al.
Publicado: (2021)

Detection of Antimicrobial Peptides in Stratum Corneum by Mass Spectrometry
por: Jenei, Adrienn, et al.
Publicado: (2021)

Antimicrobial Peptide Loss, Except for LL-37, is not Characteristic of Atopic Dermatitis
por: SZABÓ, Lilla, et al.
Publicado: (2023)

Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities
por: Crowley, JJ, et al.
Publicado: (2014)

Noninvasive assessment of cytokine and antimicrobial peptide levels in hidradenitis suppurativa using transdermal analysis patches
por: Ardon, C.B., et al.
Publicado: (2020)

Guidelines for Qualifications of Neurodiagnostic Personnel: A Joint Position Statement of the American Clinical Neurophysiology Society, the American Association of Neuromuscular & Electrodiagnostic Medicine, the American Society of Neurophysiological Monitoring, and ASET—The Neurodiagnostic Society
por: López, Jaime R., et al.
Publicado: (2023)

Review of Comorbidities of Hidradenitis Suppurativa: Implications for Daily Clinical Practice
por: Tzellos, Thrasyvoulos, et al.
Publicado: (2020)

An Integrated Approach to Unravel Hidradenitis Suppurativa Etiopathogenesis
por: Tricarico, Paola M., et al.
Publicado: (2019)

Cura tu acné : dietas y nuevos tratamientos
por: Hoehn, Gustave H.
Publicado: (1997)

Quality of Life in Hidradenitis Suppurativa: An Update
por: Chernyshov, Pavel V., et al.
Publicado: (2021)

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study
por: Kimball, A.B., et al.
Publicado: (2015)

New insights in hidradenitis suppurativa from a population‐based Dutch cohort: prevalence, smoking behaviour, socioeconomic status and comorbidities
por: Prens, Lisette M., et al.
Publicado: (2022)

Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group
por: Zouboulis, C.C., et al.
Publicado: (2018)

Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing—A Molecular Meta-Analysis
por: Zouboulis, Viktor A., et al.
Publicado: (2021)

Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional Study
por: Vossen, Allard R. J. V., et al.
Publicado: (2017)

Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa
por: Aarts, Pim, et al.
Publicado: (2021)

Bases para la atención farmacéutica del acné vulgar /
por: Sánchez Alonso, Francisco
Publicado: (2000)

Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial
por: Bechara, Falk G., et al.
Publicado: (2021)

Hidradenitis suppurativa in AIDS
por: Khambhati, Ravi, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_9em5jdu78ltb2bdhj92s0939ui